Clinical trial NCT06398678: Anesthesia Management in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Official title: Retrospective Evaluation of Anesthesia Management and Clinical Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cytoreductive Surgery
Hyperthermic Intraperitoneal Chemotherapy
Anesthesia
Lead sponsor: Sanliurfa Mehmet Akif Inan Education and Research Hospital
Sponsor class: OTHER
First posted: 2024-05-03
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study will include cases of patients over the age of 18 who underwent hyperthermic intraperitoneal chemotherapy with the closed method in accordance with the protocols determined by the Department of Surgical Oncology for 4 years retrospectively at the University of Health Sciences Şanlıurfa Mehmet Akif İnan Health Application and Research Center.

Brief summary: A combined approach of cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) represents a potential treatment option for patients diagnosed with primary or secondary gastrointestinal or gynaecological malignancies with peritoneal involvement. While the surgical phase of the operation macroscopically addresses the cancerous tissue, the HIPEC phase targets the microscopic tumour cells that remain after surgery (1). The surgical procedure known as SRC and HIPEC is one of the most complex surgical procedures, presenting numerous challenges for both the surgical and anaesthesia teams. The haemodynamic, haematological and metabolic changes that occur before, during and in the early postoperative period are associated with an increased risk of morbidity and mortality. It is therefore crucial for anaesthesia management to maintain normovolemia during surgery, compensate for hypothermia in the surgical phase and hyperthermia in the HIPEC phase, and maintain metabolic and haemodynamic balance throughout the entire procedure.

The objective of this study was to retrospectively examine the anaesthesia management and clinical outcomes in patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in order to create literature information that can facilitate the early recognition and prevention of haemodynamic, haematological and metabolic problems that occur especially in the intraoperative and postoperative period.


Eligibility criteria: Inclusion Criteria:

* patients with primary or secondary gastrointestinal or gynecologic malignancies with peritoneal involvement.
* Over 18 years of age

Exclusion Criteria:

* Over 80 years of age
* those with heart, lung and liver diseases

Primary outcomes:
measure: Anesthesia Management in Hyperthermic Intraperitoneal Chemotherapy
timeFrame: 01/01/2020 - 01/01/2024
measure: perioperative complications
timeFrame: during the operation
measure: fluid transfusion amounts
timeFrame: during the operation
measure: blood replacements
timeFrame: during the operation
measure: procedure times
timeFrame: during the operation
measure: 30-day mortality and morbidity
timeFrame: post-operative 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Şanlıurfa
country: Turkey
facility: University of Health Science Turkey Sanliurfa Mehmet Akif Inan Training and Research Hospital
Study officials:
References: